Relmada Therapeutics Inc
Change company Symbol lookup
Select an option...
RLMD Relmada Therapeutics Inc
UAVS Ageagle Aerial Systems Inc
IWSY ImageWare Systems Inc
AMPX Amprius Technologies Inc
TNC Tennant Co
CVX Chevron Corp
ACGLO Arch Capital Group Ltd
AAPL Apple Inc
BCSF Bain Capital Specialty Finance Inc
HPE Hewlett Packard Enterprise Co
Go

Health Care : Pharmaceuticals | Small Cap Value

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive and monotherapy treatment of major depressive disorder.

Price: Delayed
$2.83

Day's Change: -0.02 (-0.70%)

Bid: --

Ask: --

B/A Size: --

Day's High: 2.90

Day's Low: 2.74

Volume (Light) Today's volume of 12,565 shares is on pace to be much lighter than RLMD's 10-day average volume of 123,275 shares.: 12,565

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

The risk of loss in trading futures can be substantial. Clients must consider all relevant risk factors, including their own personal financial situation, before trading. Margin and level 2 options approval or higher is required. Not all account owners will qualify.

Dividends are converted to USD using the current rate of exchange at the end of the business day on the day the dividend went EX. Earnings are converted to USD using the current rate of exchange at the end of the business day on the day earnings were announced.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.